Concepedia

Publication | Open Access

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

DOIFull Paper Access

309

Citations

40

References

2017

Year

Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas, Shengjie Wu, Theodore Nicolaides, Tina Young Poussaint, Jason Fangusaro, Joanna J. Phillips, Arie Perry, David C. Turner,
Neuro-Oncology

Abstract

Selumetinib has promising antitumor activity in children with LGG. Rash and mucositis were the most common DLTs.

References

YearCitations

Page 1